We report on the successful treatment of two female patients with psychotic
depression with the new atypical neuroleptic drug olanzapine. A 75-year-ol
d female in patient suffering from recurrent endogenous depression with tac
tile hallucinations and co-enesthesia was refractory to a systematic sequen
tial antidepressant treatment strategy during a 39-week period. After addit
ion of the new atypical neuroleptic olanzapine to the SSRI citalopram, she
showed immediate and ongoing symptom relief. In the second case of a 57-yea
r-old female inpatient suffering from delusional depression,we observed mar
ked symptom relief and correction of the delusions of impoverishment. Olanz
apine is discussed with regard to its receptor-binding profile (antagonism
to 5-HT2A- and D1-D4 receptors) as a potential neuroleptic drug in the trea
tment of affective disorders with psychotic symptoms.